Skip to Content

Johnson & Johnson JNJ Stock Quote

| Rating as of

NYSE:JNJ

Morningstar‘s Stock Analysis JNJ

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Johnson & Johnson Announces Abiomed Acquisition to Accelerate Medical Device Innovation and Growth

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

Johnson & Johnson’s announced acquisition of Abiomed for close to $17 billion enables the redeployment of capital into rapidly growing cardiovascular technology. While the valuation appears on the high side of the range of fair value estimates, we don’t expect any major changes to our fair value estimate for Johnson & Johnson. The deal should enable an acceleration of growth for the device business that has been posting more sluggish growth over the past several years. Additionally, we don’t see the deal as having a major impact on the firm’s wide moat, since the benefits of the acquisition look partially offset by the price paid.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics JNJ

Company Profile JNJ

Business Description

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.

Contact
One Johnson and Johnson Plaza
New Brunswick, NJ, 08933
T +1 732 524-0400
Industry Drug Manufacturers - General
Most Recent Earnings Sep 30, 2022
Fiscal Year End Jan 2, 2023
Employees 144,300

Related News JNJ